Frequent Cocaine Use is Associated With Larger HIV Latent Reservoir Size
- PMID: 39250649
- PMCID: PMC11752676
- DOI: 10.1097/QAI.0000000000003472
Frequent Cocaine Use is Associated With Larger HIV Latent Reservoir Size
Abstract
Background: Cocaine-one of the most frequently abused illicit drugs among persons living with HIV [people living with HIV (PLWH)]-slows the decline of viral production after antiretroviral therapy and is associated with higher HIV viral load, more rapid HIV progression, and increased mortality.
Setting: We examined the impact of cocaine use on the CD4+ T-cell HIV latent reservoir (HLR) in virally suppressed PLWH participating in a national, longitudinal cohort study of the natural and treated history of HIV in the United States.
Methods: CD4+ T-cell genomic DNA from 434 women of diverse ancestry (ie, 75% Black, 14% Hispanic, 12% White) who self-reported cocaine use (ie, 160 cocaine users, 59 prior users, 215 non-users) was analyzed using the Intact Proviral HIV DNA Assay, measuring intact provirus per 106 CD4+ T cells.
Findings: HIV latent reservoir size differed by cocaine use (ie, median [interquartile range]: 72 [14-193] for never users, 165 [63-387] for prior users, 184 [28-502] for current users), which was statistically significantly larger in both prior (P = 0.023) and current (P = 0.001) cocaine users compared with never users.
Conclusions: Cocaine use may contribute to a larger replication competent HLR in CD4+ T cells among virologically suppressed women living with HIV. Our findings are important because women are underrepresented in HIV reservoir studies and in studies of the impact of cocaine use on outcomes among PLWH.
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures


References
-
- 32 HIV Surveillance Report, 2019. Accessed Oct 4, 2021 (Centers for Disease Control and Prevention; ) (2021).
Publication types
MeSH terms
Substances
Grants and funding
- P30 AI050409/AI/NIAID NIH HHS/United States
- U01 HL146245/HL/NHLBI NIH HHS/United States
- UL1 TR001863/TR/NCATS NIH HHS/United States
- R33 DA047011/DA/NIDA NIH HHS/United States
- U01 HL146192/HL/NHLBI NIH HHS/United States
- U01 HL146242/HL/NHLBI NIH HHS/United States
- P30 AI073961/AI/NIAID NIH HHS/United States
- U01 HL146193/HL/NHLBI NIH HHS/United States
- R61 DA047011/DA/NIDA NIH HHS/United States
- U01 HL146194/HL/NHLBI NIH HHS/United States
- U01 HL146241/HL/NHLBI NIH HHS/United States
- P30 AI027767/AI/NIAID NIH HHS/United States
- U01 HL146205/HL/NHLBI NIH HHS/United States
- P30 MH116867/MH/NIMH NIH HHS/United States
- U01 HL146204/HL/NHLBI NIH HHS/United States
- U01 HL146202/HL/NHLBI NIH HHS/United States
- UL1 TR001881/TR/NCATS NIH HHS/United States
- UL1 TR000004/TR/NCATS NIH HHS/United States
- U01 HL146203/HL/NHLBI NIH HHS/United States
- UL1 TR003098/TR/NCATS NIH HHS/United States
- P30 AI050410/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials